tetano
Editor, Senior Moderator
J Microbiol Immunol Infect
. 2023 Sep 19;S1684-1182(23)00168-8.
doi: 10.1016/j.jmii.2023.09.002. Online ahead of print. Survival benefit of a third dose of the COVID-19 vaccine among hemodialysis patients: A prospective cohort study
Tz-Heng Chen[SUP] 1 [/SUP], Yang Ho[SUP] 2 [/SUP], Hsin-Ling Tai[SUP] 3 [/SUP], Yuan-Chia Chu[SUP] 4 [/SUP], Yao-Ping Lin[SUP] 5 [/SUP], Chih-Yu Yang[SUP] 5 [/SUP], Wei-Cheng Tseng[SUP] 5 [/SUP], Shuo-Ming Ou[SUP] 5 [/SUP], Ming-Tsun Tsai[SUP] 5 [/SUP], Jinn-Yang Chen[SUP] 5 [/SUP], Tsai-Hung Wu[SUP] 5 [/SUP], Kuo-Hua Lee[SUP] 5 [/SUP], Fan-Yu Chen[SUP] 5 [/SUP], Szu-Yuan Li[SUP] 5 [/SUP], Chih-Ching Lin[SUP] 5 [/SUP], Der-Cherng Tarng[SUP] 6 [/SUP]
Affiliations
Background: Hemodialysis (HD) patients are particularly vulnerable to severe coronavirus disease 2019 (COVID-19) due to their immunocompromised state and comorbid conditions. Timely vaccination could be the most effective strategy to reduce morbidity and mortality. However, data on the survival benefit of the COVID-19 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and death among HD patients are limited, especially during the Omicron-dominant period.
Methods: In this prospective hospital-based cohort study, we identified HD patients from July 1, 2021, to April 29, 2022. The patients were divided into fully vaccinated and partially vaccinated groups. We compared the humoral response, risk of developing SARS-CoV-2 infection, and all-cause mortality between the two groups.
Results: Among the 440 HD patients included, 152 patients were fully vaccinated, and 288 patients were partially vaccinated. Patients in the fully vaccinated group exhibited higher anti-spike protein receptor-binding domain (S protein RBD) antibody levels and lower risks of all-cause mortality (adjusted hazard ratio, 0.35; 95% confidence interval, 0.17-0.73; p = 0.005) than the partially vaccinated group. However, the risk for SARS-CoV-2 infection did not significantly differ between the two groups. Irrespective of the number of vaccinations, the risk of all-cause mortality was lower in patients with anti-S protein RBD antibody levels in the higher tertile.
Conclusion: A third dose of the COVID-19 vaccine was associated with a decreased risk of all-cause mortality among HD patients during the Omicron-dominant period. A higher post-vaccination anti-S protein RBD antibody level was also associated with a lower risk of mortality.
Keywords: Anti-spike protein receptor-binding domain antibody; COVID-19 vaccine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2023 Sep 19;S1684-1182(23)00168-8.
doi: 10.1016/j.jmii.2023.09.002. Online ahead of print. Survival benefit of a third dose of the COVID-19 vaccine among hemodialysis patients: A prospective cohort study
Tz-Heng Chen[SUP] 1 [/SUP], Yang Ho[SUP] 2 [/SUP], Hsin-Ling Tai[SUP] 3 [/SUP], Yuan-Chia Chu[SUP] 4 [/SUP], Yao-Ping Lin[SUP] 5 [/SUP], Chih-Yu Yang[SUP] 5 [/SUP], Wei-Cheng Tseng[SUP] 5 [/SUP], Shuo-Ming Ou[SUP] 5 [/SUP], Ming-Tsun Tsai[SUP] 5 [/SUP], Jinn-Yang Chen[SUP] 5 [/SUP], Tsai-Hung Wu[SUP] 5 [/SUP], Kuo-Hua Lee[SUP] 5 [/SUP], Fan-Yu Chen[SUP] 5 [/SUP], Szu-Yuan Li[SUP] 5 [/SUP], Chih-Ching Lin[SUP] 5 [/SUP], Der-Cherng Tarng[SUP] 6 [/SUP]
Affiliations
- PMID: 37770324
- DOI: 10.1016/j.jmii.2023.09.002
Background: Hemodialysis (HD) patients are particularly vulnerable to severe coronavirus disease 2019 (COVID-19) due to their immunocompromised state and comorbid conditions. Timely vaccination could be the most effective strategy to reduce morbidity and mortality. However, data on the survival benefit of the COVID-19 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and death among HD patients are limited, especially during the Omicron-dominant period.
Methods: In this prospective hospital-based cohort study, we identified HD patients from July 1, 2021, to April 29, 2022. The patients were divided into fully vaccinated and partially vaccinated groups. We compared the humoral response, risk of developing SARS-CoV-2 infection, and all-cause mortality between the two groups.
Results: Among the 440 HD patients included, 152 patients were fully vaccinated, and 288 patients were partially vaccinated. Patients in the fully vaccinated group exhibited higher anti-spike protein receptor-binding domain (S protein RBD) antibody levels and lower risks of all-cause mortality (adjusted hazard ratio, 0.35; 95% confidence interval, 0.17-0.73; p = 0.005) than the partially vaccinated group. However, the risk for SARS-CoV-2 infection did not significantly differ between the two groups. Irrespective of the number of vaccinations, the risk of all-cause mortality was lower in patients with anti-S protein RBD antibody levels in the higher tertile.
Conclusion: A third dose of the COVID-19 vaccine was associated with a decreased risk of all-cause mortality among HD patients during the Omicron-dominant period. A higher post-vaccination anti-S protein RBD antibody level was also associated with a lower risk of mortality.
Keywords: Anti-spike protein receptor-binding domain antibody; COVID-19 vaccine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).